Glioma immunotherapy has attracted increasing attention since the immune system plays a
vital role in suppressing tumor growth. Immunotherapy strategies are already being tested in …

Glioma is the most common intracranial primary malignancy, with limited treatment options
and a poor overall survival (OS). Immunotherapy has been used successfully in various …

Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …

Glioblastoma is in need of innovative treatment approaches. Immune therapy for cancer
refers to the use of the body's immune system to target malignant cells in the body. Such …

Glioblastoma is the most frequent primary neoplasm of the central nervous system and still
suffers from very poor therapeutic impact. No clear improvements over current standard of …

Malignant gliomas are associated with poor prognoses despite surgical, radiation and
chemotherapy interventions. Since notable side-effects are associated with each of the …

Glioma is the most common primary brain tumor, characterized by a consistently high patient
mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial …

Simple Summary Glioblastoma is the most frequent and the most aggressive brain tumor.
Even with the most current treatment, its prognosis remains dismal. Immunotherapies, novel …

Among the malignant tumors in the central nervous system (CNS), glioma is the most
challenging tumor to the public society, which accounts for the majority of intracranial …

Introduction Gliomas are infiltrating brain tumors associated with high morbidity and
mortality. Current standard of care includes radiation, chemotherapy, and surgical resection …